Research & Publications

Summary

This study examined treatment patterns and outcomes among people with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who began ibrutinib and later experienced a treatment-related adverse events. Using large U.S. real-world datasets that include both commercially insured and Medicare populations, researchers compared patients who continued therapy at a reduced dose versus those who remained at the original full dose.

Across data sources, dose reduction was linked to longer time before the next treatment or death, fewer hospital visits, and lower CLL/SLL-related medical costs, suggesting that dose reduction may effectively manage tolerability without compromising clinical efficacy.

Key Findings

• Longer time to next treatment: Among Medicare Fee-for-Service patients, those who experienced a side effect and received a dose reduction maintained therapy for approximately twice as long as long as those who did not.
• Consistent benefit for cardiac events: Even among patients with cardiac-related side effects, dose reduction tended to extend time on treatment.
• Lower medical costs: Across insurance types, patients with dose reductions had fewer disease-related outpatient visits and lower monthly disease-related costs, in some cases by more than half.

Why This Matters

Maintaining patients on effective treatment is vital in CLL/SLL, but side effects often lead to discontinuation. These real-world findings suggest that dose reduction may help manage tolerability, help patients stay on therapy longer, and potentially reduce healthcare resource use and costs.

Read the full study: https://doi.org/10.1080/10428194.2024.2402814